Track protection status across key markets to assess launch feasibility.
It is formulated by 6 pharmaceutical companies such as MYLAN, TEVA PHARMS USA INC, DR REDDYS and others. It is marketed under 1 brand name, including SORAFENIB TOSYLATE. Available in 1 different strength, such as EQ 200MG BASE, and administered through 1 route including TABLET;ORAL.
API availability: Loading API feasibility...
Licensing: 6 potential partnersUS Launch window: Loading launch window...
Stay ahead with worldwide patent expiry and latest updates.
FDA approval history for this ingredient
Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.
Key expiration dates for US patents covering this ingredient
Stay ahead with worldwide patent expiry insights, market data, and research updates.
Latest drug strengths approved by FDA
Strength | Route of Administration | Companies | Latest Approval Date |
---|
Patents approved by the FDA for the ingredient
|
Patent Number | Publication Date | Legal Status | Patent Expiry Date | |
---|---|---|---|---|---|
{"application_id":"96794","ingredient":"SORAFENIB TOSYLATE","trade_name":"NEXAVAR","family_id":"be0b92c3a4bc42a5b27e","publication_number":"US8877933B2","cleaned_patent_number":"8877933","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-12-24","publication_date":"2014-11-04","legal_status":"Granted"} | US8877933B2 Molecular Formulation | 04 Nov, 2014 | Granted | 24 Dec, 2027 | |
{"application_id":"96834","ingredient":"SORAFENIB TOSYLATE","trade_name":"NEXAVAR","family_id":"5353692686104a5b8fc4","publication_number":"US9737488B2","cleaned_patent_number":"9737488","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-09-10","publication_date":"2017-08-22","legal_status":"Granted"} | US9737488B2 Formulation | 22 Aug, 2017 | Granted | 10 Sep, 2028 |
Latest clinical trials and research studies for this ingredient
NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
---|
Manufacturing Locations
Unlock access to all suppliers of Sorafenib Tosylate
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.